BCAB
BioAtla, Inc.Company Information
- Company Name
- BioAtla, Inc.
- CIK
- CIK0001826892
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BCAB: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- BCAB
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-12-26
- Last sale
- 2021-12-02
- Shares purchased (TTM)
- 148,295
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 267,596
- Shares outstanding
- 1,660,586
- Ownership
- 16.11%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -61.74%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Class B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable Current And Noncurrent | - | - | - | 0 | - | - | - | 2 | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 2 | 2 | 7 | 8 | 18 | 32 | 49 | 57 | 62 | 81 | 111 | 141 | ||||||
| Accounts Receivable Net Current | 2 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 2 | 5 | 2 | 4 | 5 | 6 | 5 | 6 | ||||||
| Assets Current | 4 | 3 | 8 | 10 | 21 | 38 | 51 | 61 | 66 | 86 | 116 | 148 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 5 | 5 | 6 | 6 | 6 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 10 | 9 | 14 | 16 | 27 | 38 | 52 | 62 | 69 | 89 | 120 | 151 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 19 | 19 | 16 | 17 | 16 | 15 | 14 | 18 | 16 | 18 | 27 | 34 | ||||||
| Operating Lease Liability Current | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Liabilities Current | 21 | 21 | 22 | 18 | 17 | 16 | 15 | 19 | 17 | 19 | 28 | 36 | ||||||
| Operating Lease Liability Noncurrent | 4 | 5 | 5 | 5 | 5 | - | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Liabilities | 46 | 46 | 50 | 47 | 44 | 38 | 38 | 39 | 37 | 39 | 49 | 57 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 515 | 515 | 509 | 505 | 503 | 502 | 500 | 494 | 492 | 489 | 487 | 484 | ||||||
| Retained Earnings Accumulated Deficit | -552 | -552 | -546 | -536 | -520 | -501 | -486 | -471 | -461 | -439 | -416 | -389 | ||||||
| Stockholders Equity | -36 | -37 | -36 | -31 | -17 | 1 | 14 | 23 | 31 | 50 | 71 | 95 | ||||||
| Liabilities And Stockholders Equity | 10 | 9 | 14 | 16 | 27 | 38 | 52 | 62 | 69 | 89 | 120 | 151 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | 350 | ||||||
| Common Stock Shares Issued | 2 | 2 | 63 | 59 | 59 | 58 | 58 | 48 | 48 | 48 | 48 | 48 | ||||||
| Shares Outstanding | 2 | 2 | 63 | 59 | 59 | 58 | 58 | 48 | 48 | 48 | 48 | 48 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBioAtla, Inc. (BCAB) — SEC Financial Statements & Analysis
BioAtla, Inc. (BCAB) is a biological products, (no diagnostic substances) company, incorporated in DE. BioAtla, Inc. trades on Nasdaq as: BCAB. BioAtla, Inc. (BCAB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, BioAtla, Inc. carries a market cap of $6.87M, a P/E ratio of -0.22x, a P/B ratio of -0.19x, an enterprise value of $5.33M, and an EV/EBITDA multiple of -0.17x. On profitability, it posts a Return on Equity (ROE) of 118.74% and a Return on Assets (ROA) of -171.72%. Per share, it reports EPS of $-18.94, diluted EPS of $-18.93, free cash flow per share of $-14.14, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -47.15% year-over-year and EPS growth of -62.76% year-over-year. On the balance sheet, it maintains a current ratio of 0.20x, a quick ratio of 0.17x, working capital of $-16.76M, a debt-to-equity ratio of -1.26x, a debt ratio of 4.81, free cash flow of $-23.48M (TTM), and net debt of $-1.54M. Figures sourced from SEC EDGAR.
- Market Cap
- $6.87M
- P/E TTM
- -0.22x
- EPS TTM
- $-18.94
- P/B TTM
- -0.19x
- ROE TTM
- 118.74%
- ROA TTM
- -171.72%
- Debt To Equity
- -1.26x
- Free Cash Flow TTM
- $-23.48M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BioAtla, Inc. in?
BioAtla, Inc. (BCAB) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does BCAB trade on?
BioAtla, Inc. (BCAB) trades on the Nasdaq.
Where is BioAtla, Inc. incorporated?
BioAtla, Inc. is incorporated in DE.
When was BioAtla, Inc. (BCAB)'s most recent SEC filing?
BioAtla, Inc. (BCAB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is BCAB's market cap?
BioAtla, Inc. (BCAB) has a market capitalization of $6.87M as of 2026-06-30.
What is BCAB's EPS (earnings per share)?
BioAtla, Inc. (BCAB)'s trailing twelve month EPS is $-18.94 as of 2026-06-30.
What is BCAB's ROE (return on equity)?
BioAtla, Inc. (BCAB)'s trailing twelve month Return on Equity (ROE) is 118.74% as of 2026-06-30.
What is BCAB's ROA (return on assets)?
BioAtla, Inc. (BCAB)'s trailing twelve month Return on Assets (ROA) is -171.72% as of 2026-06-30.
What is BCAB's EV/EBITDA?
BioAtla, Inc. (BCAB)'s trailing twelve month EV/EBITDA is -0.17x as of 2026-06-30.